Unresolved
We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.
Not yet answered
What are we missing?
HealthAratus Intelligence
Insilico Medicine
Insilico MedicineInsilico Medicine Intelligence
What the accumulated evidence, deployment record and lived experience actually show.
Intelligence lenses
Four ways of interrogating the same reality. Each changes the question, not the subject.
Do published findings about Insilico Medicine match what happens in practice?
Public evidence
Insilico Medicine funding signal
Google News
Public evidence
STAT+: Insilico Medicine CEO on how best to use AI in drug development
STAT Health Tech
Public evidence
Insilico Medicine signs $2.75B AI drug discovery deal with Eli Lilly
MobiHealthNews
Public evidence
STAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
STAT Health Tech
What we know · what we don’t
Everything here is open to being corrected by someone who has seen it first-hand.
What we still don’t know
Nobody has answered these yet. Your experience can help us understand what is happening.
Matters of record
Settled elsewhere. Context for reading the above, not something practice can confirm.
- 5 public external signal(s) across 4 source(s).Recorded by HealthAratus
Tool intelligence
What HealthAratus understands
HealthAratus currently understands Insilico Medicine through regulatory records, company records and external market activity.
- Category
- life_sciences_drug_discovery
What HealthAratus is still learning
HealthAratus is beginning to understand Insilico Medicine. As evidence and experience accumulate, what remains unclear will be stated here.
Evidence & claims
What this is built on
The material the questions above were built from, with its attribution.
Insilico Medicine uses artificial intelligence to identify therapeutic targets and design drug candidates. The company integrates deep learning and automation across its Pharma.AI platform to support drug discovery.According to Insilico Medicine
What Insilico Medicine states
The vendor’s own claims. Testable where practice can actually test them.
Stated capability
The company uses AI to design novel molecular structures for drug candidates.
According to Insilico Medicine
Does this change your workflow?
Independent and public evidence
Found in public sources. Not a clinician’s experience, and never presented as one.
Reported deployment
STAT+: Insilico Medicine CEO on how best to use AI in drug development
According to STAT Health Tech
How widely is this actually used?
Reported deployment
Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration
According to HIT Consultant
How widely is this actually used?
Reported deployment
Insilico Medicine signs $2.75B AI drug discovery deal with Eli Lilly
According to MobiHealthNews
How widely is this actually used?
Reported deployment
STAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
According to STAT Health Tech
How widely is this actually used?
Company participation
Not yet verified
A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.
Claim your company profileReference
The stable facts, for interpreting everything above.
Overview
What it does
• Insilico Medicine is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in AI-driven drug discovery and development. Founded in 2014, the company integrates artificial intelligence, deep learning, and automation to accelerate the identification of novel therapeutic targets and the design…
Vendor & external product information, not independently verified by HealthAratus
Where it's used
Deployed in lab settings, United States, China, Canada, Middle East
Key strength
Regulatory: FDA clearance for clinical trials of INS018_055, EMA approval for clinical trials in Europe
Key limitation
Research-stage, not yet commercially deployed
Key capabilities
Proprietary AI platform, Pharma.AI, integrating modules like PandaOmics, Chemistry42, and inClinico, Generative adversarial networks (GANs) for novel compound generation, Deep learning algorithms for target identification and drug design
Clinical use cases
Development of INS018_055, the first fully AI-generated drug, for idiopathic pulmonary fibrosis, Oncology therapies targeting novel pathways identified through AI-driven discovery, Immunology treatments based on AI-identified targets
Who uses it
Pharmaceutical companies seeking AI-driven drug discovery solutions, Biotech firms aiming to accelerate therapeutic development, Research institutions interested in AI applications in drug discovery
Parent Company
Insilico Medicinevendor
How the reality here has changed
Not enough recorded activity across time yet to describe how the reality here has moved. As accounts of Insilico Medicine accumulate, this becomes a record of how the reality moved rather than a snapshot of one moment.
Across the category
Insilico Medicine against the rest of Life Sciences / Drug Discovery
Category intelligence reads this as Established. A sample of peers, not a census of the category.
Across Life Sciences / Drug Discovery
Only patterns carried by more than one system. One system’s activity is that system’s story.
- 3accuracy quality — reported across 3 systems
- 2adoption state — reported across 2 systems
- 2time saved — reported across 2 systems
- 2workflow friction — reported across 2 systems
Where Insilico Medicine may differ
Differences in what we have recorded. Never a ranking, never a quality judgement.
No first-hand account has been recorded for Insilico Medicine or for any peer we sampled in this category.
A gap across the whole category, not a fact about this technology.
Still unresolved across the category
Raised repeatedly by public activity, answered by nobody who has used these systems.
- Accuracy quality is reported across 3 systems in this category, but no first-hand account has described it.
- Adoption state is reported across 2 systems in this category, but no first-hand account has described it.
- Time saved is reported across 2 systems in this category, but no first-hand account has described it.
Two readings that disagree
- Category intelligence reads clinical reality here as "Developing", yet no first-hand account appears in the systems we sampled. Both readings are shown rather than reconciled.
Used another system in Life Sciences / Drug Discovery? How does your experience compare?
Nobody has answered accuracy quality anywhere in this category yet.
Connected intelligence
Category intelligence